Key statistics dashboard for Mereo BioPharma Group plc (MREO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment.
Stock Data
| Price | $0.27 |
| Market Cap | $42M |
| Beta | 0.38 |
| Exchange | NASDAQ |
| Country | GB |
Valuation Multiples
| P/E Ratio | -1.57 |
| Price / Book | 1.60 |
| P/S | 0.00 |
| P/FCF | -1.79 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 5.88 |
| Quick Ratio | 5.88 |
| Cash Ratio | 5.31 |
| Debt / Equity | 0.04 |
| Debt / Assets | 2.97% |
| Interest Coverage | -393.73 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -8.98 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.18 |
| Cash per share | 0.19 |
| FCF per share | -0.16 |
| Tangible Book Value per share | 0.18 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.62 |
Related companies: ACIU · ALDX · CADL · CAPR · CTNM · IMMP · KYTX
Explore sector: Healthcare · Biotechnology
More sections of MREO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks